scholarly journals Oligoastrocytoma: A Vanishing Tumor Entity

10.5772/63240 ◽  
2016 ◽  
Author(s):  
Marta Mellai ◽  
Laura Annovazzi ◽  
Marta Mazzucco ◽  
Davide Schiffer
Keyword(s):  
Tumor Entity

scholarly journals High-grade astrocytoma with piloid features (HGAP): the Charité experience with a new central nervous system tumor entity

2021 ◽  
Author(s):  
Katja Bender ◽  
Eilís Perez ◽  
Mihaela Chirica ◽  
Julia Onken ◽  
Johannes Kahn ◽  
...  
Keyword(s):  
Dna Methylation ◽  
Central Nervous System ◽  
Nervous System ◽  
World Health ◽  
Central Nervous System Tumor ◽  
High Grade ◽  
Thoracic Spinal Cord ◽  
High Grade Astrocytoma ◽  
Tumor Entity

Abstract Purpose High-grade astrocytoma with piloid features (HGAP) is a recently described brain tumor entity defined by a specific DNA methylation profile. HGAP has been proposed to be integrated in the upcoming World Health Organization classification of central nervous system tumors expected in 2021. In this series, we present the first single-center experience with this new entity. Methods During 2017 and 2020, six HGAP were identified. Clinical course, surgical procedure, histopathology, genome-wide DNA methylation analysis, imaging, and adjuvant therapy were collected. Results Tumors were localized in the brain stem (n = 1), cerebellar peduncle (n = 1), diencephalon (n = 1), mesencephalon (n = 1), cerebrum (n = 1) and the thoracic spinal cord (n = 2). The lesions typically presented as T1w hypo- to isointense and T2w hyperintense with inhomogeneous contrast enhancement on MRI. All patients underwent initial surgical intervention. Three patients received adjuvant radiochemotherapy, and one patient adjuvant radiotherapy alone. Four patients died of disease, with an overall survival of 1.8, 9.1, 14.8 and 18.1 months. One patient was alive at the time of last follow-up, 14.6 months after surgery, and one patient was lost to follow-up. Apart from one tumor, the lesions did not present with high grade histology, however patients showed poor clinical outcomes. Conclusions Here, we provide detailed clinical, neuroradiological, histological, and molecular pathological information which might aid in clinical decision making until larger case series are published. With the exception of one case, the tumors did not present with high-grade histology but patients still showed short intervals between diagnosis and tumor progression or death even after extensive multimodal therapy.

Tall cell carcinoma with reversed polarity: A case report of a very rare breast tumor entity and mini‐review

2021 ◽  
Vol 27 (4) ◽  
pp. 369-376
Author(s):  
Helen J. Trihia ◽  
Pavlos Lampropoulos ◽  
Loukas Karelis ◽  
Efthymia Souka ◽  
Georgios Galanopoulos ◽  
...  
Keyword(s):  
Case Report ◽  
Cell Carcinoma ◽  
Breast Tumor ◽  
Tall Cell ◽  
Tumor Entity ◽  
Reversed Polarity

scholarly journals An activating germline IDH1 variant associated with a tumor entity characterized by unilateral and bilateral chondrosarcoma of the mastoid

2020 ◽  
Vol 1 (1) ◽  
pp. 100006
Author(s):  
Patrick R. Blackburn ◽  
Jodi M. Carter ◽  
Devin Oglesbee ◽  
Jennifer J. Westendorf ◽  
Brian A. Neff ◽  
...  
Keyword(s):  
Tumor Entity

scholarly journals Leiomyosarcoma of intravascular origin - a rare tumor entity: clinical pathological study of twelve cases

2010 ◽  
Vol 8 (1) ◽  
Author(s):  
Daniel J Tilkorn ◽  
Joerg Hauser ◽  
Andrej Ring ◽  
Ole Goertz ◽  
Ingo Stricker ◽  
...  
Keyword(s):  
Rare Tumor ◽  
Pathological Study ◽  
Tumor Entity

scholarly journals A compound follicular-parafollicular cell carcinoma of the thyroid: A new tumor entity?

Cancer ◽  
1983 ◽  
Vol 52 (6) ◽  
pp. 1053-1061 ◽  
Author(s):  
Otto Ljungberg ◽  
Ulla-Britt Ericsson ◽  
Lennart Bondeson ◽  
Jan Thorell
Keyword(s):  
Cell Carcinoma ◽  
Parafollicular Cell ◽  
Tumor Entity

scholarly journals Adenomatoid odontogenic tumor: A fluctuating tumor entity

2016 ◽  
Vol 3 (5) ◽  
pp. 170-172
Author(s):  
V. Keerthi Narayan ◽  
H. C. Girish ◽  
Sanjay Murgod ◽  
M. Sai Kavya ◽  
L. Nishanthi
Keyword(s):  
Odontogenic Tumor ◽  
Adenomatoid Odontogenic Tumor ◽  
Tumor Entity

scholarly journals Erratum to: Gliomatosis cerebri: no evidence for a separate brain tumor entity

2016 ◽  
Vol 131 (2) ◽  
pp. 321-322 ◽  
Author(s):  
Ulrich Herrlinger ◽  
David T. W. Jones ◽  
Martin Glas ◽  
Elke Hattingen ◽  
Dorothee Gramatzki ◽  
...  
Keyword(s):  
Brain Tumor ◽  
Gliomatosis Cerebri ◽  
Tumor Entity

scholarly journals Sprouty3, but Not Sprouty1, Expression Is Beneficial for the Malignant Potential of Osteosarcoma Cells

2021 ◽  
Vol 22 (21) ◽  
pp. 11944
Author(s):  
Anna Zita Mehira Kamptner ◽  
Christoph-Erik Mayer ◽  
Hedwig Sutterlüty
Keyword(s):  
Receptor Tyrosine Kinase ◽  
Ectopic Expression ◽  
Soft Agar ◽  
Tumor Promoter ◽  
Cellular Behavior ◽  
Cell Proliferation And Migration ◽  
Extracellular Signal ◽  
Tumor Entity ◽  
And Migration ◽  
Proliferation And Migration

Sprouty proteins are widely accepted modulators of receptor tyrosine kinase-associated pathways and fulfill diversified roles in cancerogenesis dependent on the originating cells. In this study we detected a high expression of Sprouty3 in osteosarcoma-derived cells and addressed the question of whether Sprouty3 and Sprouty1 influence the malignant phenotype of this bone tumor entity. By using adenoviruses, the Sprouty proteins were expressed in two different cell lines and their influence on cellular behavior was assessed. Growth curve analyses and Scratch assays revealed that Sprouty3 accelerates cell proliferation and migration. Additionally, more colonies were grown in Soft agar if the cells express Sprouty3. In parallel, Sprouty1 had no significant effect on the measured endpoints of the study in osteosarcoma-derived cells. The promotion of the tumorigenic capacities in the presence of Sprouty3 coincided with an increased activation of signaling as measured by evaluating the phosphorylation of extracellular signal-regulated kinases (ERKs). Ectopic expression of a mutated Sprouty3 protein, in which the tyrosine necessary for its activation was substituted, resulted in inhibited migration of the treated cells. Our findings identify Sprouty3 as a candidate for a tumor promoter in osteosarcoma.

scholarly journals Identification of Prognostic Organic Cation and Anion Transporters in Different Cancer Entities by In Silico Analysis

2020 ◽  
Vol 21 (12) ◽  
pp. 4491
Author(s):  
Bayram Edemir
Keyword(s):  
Organic Cation ◽  
Organic Anion ◽  
Gene Expression Pattern ◽  
Specific Gene ◽  
Organic Anion Transporters ◽  
Organic Cation Transporters ◽  
Next Generation Sequencing Technology ◽  
Anion Transporters ◽  
Tumor Entity ◽  
Cation Transporters

The information derived from next generation sequencing technology allows the identification of deregulated genes, gene mutations, epigenetic modifications, and other genomic events that are associated with a given tumor entity. Its combination with clinical data allows the prediction of patients’ survival with a specific gene expression pattern. Organic anion transporters and organic cation transporters are important proteins that transport a variety of substances across membranes. They are also able to transport drugs that are used for the treatment of cancer and could be used to improve treatment. In this study, we have made use of publicly available data to analyze if the expression of organic anion transporters or organic cation transporters have a prognostic value for a given tumor entity. The expression of most organic cation transporters is prognostic favorable. Within the organic anion transporters, the ratio between favorable and unfavorable organic anion transporters is nearly equal for most tumor entities and only in liver cancer is the number of unfavorable genes two times higher compared to favorable genes. Within the favorable genes, UNC13B, and SFXN2 cover nine cancer types and in the same way, SLC2A1, PLS3, SLC16A1, and SLC16A3 within the unfavorable set of genes and could serve as novel target structures.

Sign in / Sign up

Export Citation Format

Share Document